Literature DB >> 11888235

Neuropathic pain: evidence matters.

Henry J McQuay1.   

Abstract

"He slept less and less; they gave him opium and began to inject morphine. But this did not relieve him. The dull pain he experienced in the half asleep condition at first only relieved him as a change, but then it became as bad, or even more agonizing, than the open pain."--Tolstoy, The Death of Ivan Ilyitch. It comes as a surprise to many pharmacologists that not all pains are relieved by opioids. Those who work in chronic pain are unfortunately only too aware of the problems that such pains can cause. One of the hallmarks of neuropathic pain is poor or incomplete relief with opioids. As with so many things in medicine, there is nothing novel in this realization, as the Tolstoy quotation shows. Copyright 2002 European Federation of Chapters of the International Association for the Study of Pain

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888235     DOI: 10.1053/eujp.2001.0316

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  9 in total

Review 1.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

2.  Investigation into the role of P2X(3)/P2X(2/3) receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiological study.

Authors:  Caroline J Sharp; Alison J Reeve; Sue D Collins; Jo C Martindale; Scott G Summerfield; Becky S Sargent; Simon T Bate; Iain P Chessell
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

3.  Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model.

Authors:  E Ballini; C Virginio; S J Medhurst; S G Summerfield; L Aldegheri; A Buson; C Carignani; Y H Chen; A Giacometti; I Lago; A J Powell; W Jarolimek
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.

Authors:  W Chen; J A McRoberts; J C G Marvizón
Journal:  Neuroscience       Date:  2014-02-26       Impact factor: 3.590

5.  Regression of diabetic complications by islet transplantation in the rat.

Authors:  A Remuzzi; R Cornolti; R Bianchi; M Figliuzzi; C Porretta-Serapiglia; N Oggioni; V Carozzi; L Crippa; F Avezza; F Fiordaliso; M Salio; G Lauria; R Lombardi; G Cavaletti
Journal:  Diabetologia       Date:  2009-09-30       Impact factor: 10.122

6.  Spinal cord stimulation for neuropathic pain: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

7.  Treatment considerations in neuropathic pain.

Authors:  Raphael J Leo
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

Review 8.  Management of chronic pain in the elderly: focus on transdermal buprenorphine.

Authors:  Nalini Vadivelu; Roberta L Hines
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

9.  Delta-opioid receptor analgesia is independent of microglial activation in a rat model of neuropathic pain.

Authors:  Joanna Mika; Katarzyna Popiolek-Barczyk; Ewelina Rojewska; Wioletta Makuch; Katarzyna Starowicz; Barbara Przewlocka
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.